MoonLake Immunotherapeutics (MLTX)
NASDAQ (CM) NASDAQ (CM) Primary 
MoonLake Immunotherapeutics: The Bull Case Does Not Require Clinical Supremacy
MoonLake Immunotherapeutics offers a compelling investment case despite sonelokimab's mixed clinical results, focusing on regulatory progress and commercial viability. MLTX can file for HS approval without another major trial, accelerating potential revenue and reducing dilution risk, with cash runway projected through mid-2028. Sonelokimab's durability and differentiated nanobody structure support its commercial potential, but competitive execution and access will be key to market success.
Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?
The consensus price target hints at a 73.4% upside potential for MOONLAKE IMMUNO (MLTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
MoonLake: 'Buy' Sonelokimab BLA Submission HS September And Label Expansion
MoonLake Immunotherapeutics maintains a Buy rating, supported by positive FDA interactions and strong long-term data for sonelokimab in hidradenitis suppurativa [HS]. MLTX expects to submit a BLA for sonelokimab in HS by end of September 2026, targeting both adults and adolescents, with possible acceptance for review by November 2026. 52-week VELA data show 67.2% HiSCR75 response, positioning sonelokimab as a potential best-in-class therapy and supporting a broad label proposal thanks to VELA-TEEN adolescent study.
MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript
MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript
Avoro Capital Advisors LLC Cuts Stock Position in MoonLake Immunotherapeutics $MLTX
Avoro Capital Advisors LLC lessened its holdings in shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) by 51.8% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,000,000 shares of the company's stock after selling 2,150,000 shares during the period. MoonLake
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of “Hold” from Analysts
MoonLake Immunotherapeutics (NASDAQ: MLTX - Get Free Report) has been assigned a consensus recommendation of "Hold" from the sixteen analysts that are presently covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and seven have issued a buy rating on the
MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal
MoonLake Immunotherapeutics is downgraded from Strong Buy to Buy following a mixed phase 3 outcome for sonelokimab in hidradenitis suppurativa [HS]. Despite VELA-2's primary endpoint miss, the FDA's positive Type B meeting allows MLTX to file a BLA for HS using existing VELA-1, VELA-2, and MIRA data. MLTX advances sonelokimab in multiple inflammatory indications, with strong phase 2 axSpA results [81% ASAS40 at Week 12] and upcoming phase 3 PsA data in 2026.
MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript
MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript
BioTech Breakout: MoonLake Up 30% On FDA Wins
In a stock market currently obsessed with interest rate cuts and the artificial intelligence (AI) boom, it is easy to overlook the biotechnology sector. However, for investors willing to look beyond the Magnificent Seven, clinical-stage biotech remains one of the few places to find massive, event-driven returns that are largely independent of the broader economy.
MoonLake: Ignore The Panic, Catch The Upside
MoonLake Immunotherapeutics is rated Buy, with sonelokimab having multiple dermatology and rheumatology indications. MLTX's VELA-1 trial succeeded, and VELA-2's statistical miss was due to elevated placebo response, not drug failure; combined analysis remains highly significant. Regulatory precedent, a strong financial runway into 2027, and multiple upcoming catalysts support a compelling asymmetric risk-reward profile for MLTX.
MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout
MoonLake jumps 18% after a report says MRK made a $3 billion-plus offer earlier this year, with talks potentially set to resume.
MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest
MoonLake Immunotherapeutics completed enrollment of the two phase 3 VELA studies using Sonelokimab for the treatment of patients with hidradenitis suppurativa. The global psoriatic arthritis market is projected to reach $24.2 billion by the end of 2031. Merck's $3 billion non-binding acquisition offer highlights significant buyout potential of company and validates its late-stage pipeline value.
